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Background: Comorbid diabetes and substance use diagnoses (SUD) represent a hazardous combination,
both in terms of healthcare cost andmorbidity. To date, there is limited information about the association
of SUD and related mental disorders with type 2 diabetes mellitus (T2DM).
Methods: We examined the associations between T2DM and multiple psychiatric diagnosis categories,
with a focus on SUD and related psychiatric comorbidities among adults with T2DM. We analyzed elec-
tronic health record (EHR) data on 170,853 unique adults aged ≥18 years from the EHR warehouse of a
large academic healthcare system. Logistic regression analyses were conducted to estimate the strength
of an association for comorbidities.
Results: Overall, 9% of adults (n=16,243) had T2DM. Blacks, Hispanics, Asians, and Native Americans had
greater odds of having T2DM than whites. All 10 psychiatric diagnosis categories were more prevalent
among adults with T2DM than among those without T2DM. Prevalent diagnoses among adults with
T2MD were mood (21.22%), SUD (17.02%: tobacco 13.25%, alcohol 4.00%, drugs 4.22%), and anxiety diag-
noses (13.98%). Among adultswith T2DM, SUDwas positively associatedwithmood, anxiety, personality,
somatic, and schizophrenia diagnoses.
Conclusions: We examined a large diverse sample of individuals and found clinical evidence of SUD and
psychiatric comorbidities among adults with T2DM. These results highlight the need to identify feasible
collaborative care models for adults with T2DM and SUD related psychiatric comorbidities, particularly
in primary care settings, that will improve behavioral health and reduce health risk.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC. Introduction
Theprevalenceofdiagnoseddiabetes amongUnitedStates (U.S.)
dults aged ≥18 years increased steadily from 3.5% in 1980 to
.0% in 2011 (CDC, 2014a). Currently, an estimated 29.1 million
mericans have diabetes (ADA, 2015). Type 2 diabetes mellitus
T2DM) accounts for 90–95% of individuals with diabetes (ADA,
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c-nd/4.0/).BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2014). In the U.S., individuals with diagnosed diabetes have, on
average, medical expenditures 2.3 times higher than those with-
out diabetes (ADA, 2013). The total estimated cost of diagnosed
diabetes (type 1 or 2) was $245 billion in 2012 (a 41% increase
from a prior estimate in 2007), which included $176 billion in
direct medical costs and $69 billion in increased absenteeism
and reduced productivity (ADA, 2013). The economic burden is
expected to escalate as the prevalence of T2DM continues to rise.
Increasing costs will be particularly driven by adults with multi-
ple chronic conditions, including substance use disorders (SUDs;
Ashman et al., 2014; Jiang et al., 2014). Having diabetes plus SUD
(and/or other psychiatric disorders) represents a hazardous com-
bination, both in terms of healthcare cost and morbidity. SUD and
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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affective, chronic hypomanic, chronic depressive, schizoid, introverted, schizoty-
pal, explosive, compulsive, histrionic, dependent, antisocial, narcissistic, avoidant,
borderline, passive-aggressive), somatic (somatization, conversion, hypochondria-L.-T. Wu et al. / Drug and Alcoh
ental health comorbidity can compromise patients’ adherence to
reatment for T2DM, exacerbate existing medical conditions, and
eighten the risk for premature mortality among individuals with
iabetes (Ducat et al., 2014; Ghitza et al., 2013; Vinogradova et al.,
010). Notably, inpatient care constitutes themajor part ofmedical
xpenditures for diabetes (ADA, 2013). In the nonelderly Medicaid
opulation (<65 years), individualswith either a diabetes diagnosis
ith complications, SUD, or a mental disorder (mood, schizophre-
ia, psychotic) use more inpatient care than patients without such
iagnoses (Jiang et al., 2014). Diabetes, SUD, and mental diag-
oses also are among the leading medical conditions associated
ith elevated 30-day hospital readmission rates (Jiang and Wier,
010).
The fact that some antipsychotics and antidepressants may
nduce metabolic side effects or signiﬁcant weight gain is one
eason for the co-comorbidity of mood/anxiety disorders and
chizophrenia with T2DM (De Hert et al., 2009; Nielsen et al., 2010;
harma et al., 2014). However, there are limited data about SUD
nd mental diagnoses other than mood/anxiety and schizophrenia
iagnoses among adults with T2DM. Self-reported diabetes data
romcommunity sample surveysare limitedbyanon-speciﬁcques-
ion about diabetic history,whichmaynot be equivalent to patients
n real-world clinical settings who have medical documentation of
diabetic diagnosis. Speciﬁcally, cigarette smoking is associated
ith T2DM in a dose-dependent manner, and it constitutes a risk
actor for diabetes-related complications and premature mortality
or many diseases (cardiovascular, pulmonary conditions; Ghitza
t al., 2013;Willi et al., 2007). Therefore, quantifying theprevalence
f nicotine dependence is critical for people with diabetes (Willi
t al., 2007). Survey data from the Behavioral Risk Factor Surveil-
ance System estimated that 15.4% of adults aged ≥18 years with
elf-reported diabetes (“Have you ever been told by a doctor that
ou have diabetes?”) were current cigarette smokers (Fan et al.,
013); however, the extent of tobacco use disorder among adults
ith T2DM is unclear.
Similarly, data is lacking on the prevalence of alcohol and (illicit)
rug use disorders in medical settings to inform SUD screening
nd treatment for adults with T2DM (Ghitza et al., 2013). While
ow-to-moderate alcohol use is associated with decreased odds of
aving T2DM, binge or heavy alcohol use increases the risk of T2DM
Baliunas et al., 2009; Pietraszek et al., 2010), demonstrating the
eed to identify and treat alcohol use diagnoses among individ-
als with diabetes. A prior study of 65,996 adults with diabetes
ho received care through Kaiser Permanente Northern California
nd responded to a survey of alcohol use indicated that 51% of
dults with diabetes reported current alcohol use (Ahmed et al.,
006). A greater number of drinks per day were associated with
decreased probability of complying with diabetes care. Another
tudy of male outpatients with diabetes (n=3930) from 7 Veter-
ns Affairs sites suggested that 13% of adults with diabetes had
lcohol use problems (Alcohol Use Disorders Identiﬁcation Test-
onsumption [AUDIT-C] score ≥4) and that higher AUDIT-C scores
ere associated with poorer diabetes self-care (Thomas et al.,
006). Both studies of adultswith diabetes inmedical settings indi-
ate that problematic or frequent alcohol use can impair diabetes
elf-care behaviors, yet alcohol use diagnosis data were not avail-
ble (Ahmed et al., 2006; Thomas et al., 2006). Chronic misuse of
llicit or nonmedical psychoactive drugs may also increase psychi-
tric problems, worsenmedical sequelae of diabetes, or complicate
iabetes self-care (Brick, 2004; Leung et al., 2011a,b; Volkow et al.,
014). Reliable estimates of drug use disorders by T2DM status are
acking, but are needed to inform targeted screening and interven-
ions.
Taken together, the heavy economic burden associated with
iabetes is disproportionally inﬂuencedby individualswith comor-
id diabetes and SUD disorders, particularly those with both SUDendence 156 (2015) 162–169 163
and mental disorders (ADA, 2013; Ghitza et al., 2013; Jiang et al.,
2014). Given the lack of information on patterns of comorbid-
ity, we leveraged data from an electronic health record (EHR)
warehouse to determine the extent of SUD and related psychi-
atric comorbidities by T2DM status. Since <1% of young people
aged <20 years have diagnosed diabetes (CDC, 2014b), we focused
on T2DM in adults. We examined the prevalence of T2DM
and determined associations of psychiatric diagnoses (alcohol,
tobacco, drug, schizophrenia/psychotic,mood, anxiety, personality,
somatic, and disruptive behavioral disorder diagnoses) with T2DM
status. Among adultswith T2DM,we examined associations of SUD
with mental diagnoses, in order to gauge multi-comorbidity. To
control for age-related increases inmedical problems, we stratiﬁed
the analyses by age group.
2. Methods
2.1. Data sources
We analyzed the EHR data of unique adults aged ≥18 years from the
Duke Medicine Enterprise Data Warehouse (EDW) between January 1, 2007 and
December 31, 2011 (i.e., patients were≥18 years as of January 1, 2007). The primary
group of interest was comprised of patients with a T2DM diagnosis (n=16,243);
this group was compared with patients without T2DM (n=154,610). Patients aged
≥18 years with type 1 diabetes (ICD-9-CM diagnosis codes) were excluded from
the analysis (n=2650), resulting in a sample of 170,853 patients. Brieﬂy, the EHR
dataset for this analysiswas identiﬁedanddeveloped for theDurhamDiabetesCoali-
tion project, which leverages EHR data to inform community-based interventions
that seek to improve population-level diabetes management, health outcomes, and
quality of life for adults living with T2DM in Durham County (Spratt et al., 2015). A
geographic health information system was employed to link the EHR and patients’
social and environmental data in order to provide a multidimensional understand-
ing of environmental contexts and vulnerabilities for adults living with T2DM in
Durham, North Carolina, and to develop tailored community-based interventions.
An estimated 80% of Durham County residents received care from a Duke Medicine
provider at some point during the interval of 2007–2011. Durham County is located
in the Central Piedmont region of North Carolina. Compared with the overall U.S.
population, Durham County has a higher proportion of the “Black/African Ameri-
can alone” population (13.2% vs. 38.7%) and lower proportions of the “White alone”
(77.7% vs. 53.1%) and “Hispanic/Latino” populations (17.1% vs. 13.5%) (U.S. Census
Bureau, 2015).
2.2. Study variables
Demographic variables included age (as of January 1, 2007), sex, patient-
identiﬁed race (WhiteorCaucasian,American IndianorAlaskaNative,Asian, Blackor
AfricanAmerican,multiracial, NativeHawaiianor Paciﬁc Islander, other, declined, or
unavailable), andpatient-identiﬁedethnicity (Hispanicornon-Hispanic).Diagnostic
variableswere based on ICD-9-CMcodes (CMS, 2008). Common conditions that tend
to be associated with diabetes, including chronic obstructive pulmonary disease
(COPD), hypertensive disease, ischemic heart disease, and renal disease (nephritis,
nephrotic syndrome, nephrosis), were included as control variables for the analysis
of comorbidity (Heron, 2013). We also controlled for the overall number of health-
care encounters (outpatient, inpatient, emergency department) during 2007–2011
to mitigate the confounding effects of healthcare utilization, since those who use
healthcare frequentlymay have an increased diagnostic probability (Jiang andWier,
2010).
We used the published crosswalk of Diagnostic and StatisticalManual ofMental
Disorders, Fourth Edition, Text Revision (DSM-IV-TR) codes to ICD-9-CM codes from
the American Psychological Association (APA) Practice Organization to deﬁne psy-
chiatric diagnoses that are consistent with DSM-IV-TR categories (APA, 2002). The
crosswalk lists each speciﬁc ICD-9-CM diagnosis code corresponding to a DSM-IV-
TR diagnosis code. Psychiatric disorder diagnoses included alcohol use, tobacco use,
druguse (cannabis, amphetamines, cocaine, hallucinogens, inhalants, opioids, phen-
cyclidine, sedatives, hypnotics, or anxiolytics), schizophrenia or psychotic mood
(major depressive, bipolar, manic, manic-depressive), anxiety (panic, generalized
anxiety, phobia, obsessive-compulsive, posttraumatic stress), personality (paranoid,sis, psychogenic pain-site unspeciﬁed), and disruptive behavioral disorder (conduct,
impulse-control) diagnoses (APA, 2002). A patient was considered to have a given
diagnosis if an ICD-9-CM code for that conditionwas found in the list of discharge or
ﬁnal diagnosis codes for any type of encounter (inpatient, outpatient) at least once
during 2007–2011.
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Table 1
Characteristics of adults aged 18 or older by T2DM.a
Variables Overall
n=170,853
With T2DM
n=16,243
Without T2DM
n=154,610
Adjusted OR of
T2DM (95% CI)
Age (overall)b 1.22 (1.20, 1.23)
Mean (SD) 41.6 (17.4) 56.6 (15.6) 40.0 (16.8)
%c %d %d
Age groups, years
18–35 76,297 (44.7%) 1586 (2.1%) 74,711 (97.9%) 1.00
36–50 44,514 (26.1%) 4016 (9.0%) 40,498 (91.0%) 2.24 (2.10, 2.39)
51–64 30,441 (17.8%) 5638 (18.5%) 24,803 (81.5%) 3.41 (3.19, 3.64)
65 and older 19,601 (11.5%) 5003 (25.5%) 14,598 (74.5%) 3.23 (3.01, 3.47)
Sex
Female 98,178 (57.5%) 9130 (9.3%) 89,048 (90.7%) 1.00
Male 72,591 (42.5%) 7113 (9.8%) 65,478 (90.2%) 1.24 (1.20, 1.29)
Unknown 83 (0.0%) 0 (0.0%) 83 (100.0%)
Race
Alaskan Native or American Indian 587 (0.3%) 51 (8.7%) 536 (91.3%) 2.43 (1.75, 3.37)
Asian 6115 (3.6%) 269 (4.4%) 5846 (95.6%) 1.50 (1.31, 1.73)
Black or African American 59,552 (34.9%) 8705 (14.6%) 50,847 (85.4%) 2.07 (1.98, 2.15)
Multiracial 1179 (0.7%) 75 (6.4%) 1104 (93.6%) 2.12 (1.63, 2.76)
Others/unknown 21,553 (12.6%) 870 (4.0%) 20,683 (96.0%) 1.56 (1.41, 1.73)
White or Caucasian 81,867 (47.9%) 6273 (7.7%) 75,594 (92.3%) 1.00
Ethnicity
Hispanic 11,503 (6.7%) 545 (4.7%) 10,958 (95.3%) 1.62 (1.43, 1.84)
Non-Hispanic 159,350 (93.3%) 15,698 (9.9%) 143,652 (90.1%) 1.00
Medical diagnosis, yes
COPD 16,120 (9.4%) 3472 (21.5%) 12,648 (78.5%) 1.17 (1.11, 1.22)
Hypertensive disease 46,496 (27.2%) 13,365 (28.7%) 33,131 (71.3%) 6.94 (6.59, 7.31)
Ischemic heart disease 10,108 (5.9%) 3908 (38.7%) 6200 (61.3%) 1.51 (1.43, 1.59)
Renal diseasee 8657 (5.1%) 3612 (41.7%) 5045 (58.3%) 1.58 (1.50, 1.67)
Log base 10 of the number of encountersf
Median (25th, 75th) 8.0 (3.0, 24.0) 28.0 (11.0, 56.0) 7.0 (2.0, 20.0) 1.86 (1.79, 1.93)
Note. All ORs, with the exception of those for the age group variable, were derived from this logistic model: T2DM as predicted by continuous age, sex, race, ethnicity,
individual comorbidities, and log base 10 of the number of patient encounters. A separate model used to calculate ORs for the age group variable was the same as above, with
the exception that age group was substituted for continuous age.
Abbreviations: CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; OR, odds ratio; SD, standard deviation; T2DM, type 2 diabetes mellitus.
a Population excludes patients who have type 1 diabetes.
b Reference for computation of OR is 10-year increase in age.
c Proportions are within the column.
d Proportions are across rows.
e Renal disease: nephritis, nephrotic syndrome, or nephrosis.
f Base 10 log transformation was applied to the number of healthcare encounters due to skewness.
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H.3. Statistical analysis
We examined frequencies for study variables by T2DM status and used logistic
egression analyses to determine associations of demographics, medical variables,
umber of healthcare encounters, and inpatient treatment with T2DM status. We
hen examined the prevalence of psychiatric diagnoses by T2DM status. To con-
rol for age difference in health status, we stratiﬁed the analysis by age group. We
onducted logistic regression analyses to determine associations of each psychi-
tric diagnosis with T2DM, adjusting for age, sex, race, ethnicity, and number of
ealthcare encounters. Finally, among patients with T2DM, we conducted logistic
egression analyses to determine the association of SUD with psychiatric diagnoses,
djusting for age, sex, race, ethnicity, COPD, hypertensive disease, ischemic heart
isease, renal disease, and number of healthcare encounters. We report 95% con-
dence intervals (CIs) for prevalence and adjusted odds ratio (OR) estimates. All
nalyses were performed using SAS® software, version 9.2 (SAS Institute, Inc., Cary,
C).
. Results.1. Demographics
Of 170,853 adults aged 18–90 years, 57.5% were female, 11.5%
ere older (aged 65–90 years), 34.9% were black, and 6.7% were
ispanic.3.2. Factors associated with T2DM (Table 1)
Overall, 9% (n=16,243) of the sample had T2DM. Prevalence of
T2DM increased with age strata (18.5%, aged 51–64; 25.5%, aged
65–90 years),was higher inmen (9.8% vs. 9.3% inwomen) and black
adults (14.6% vs. 7.7% in whites), and was elevated among adults
with COPD (21.5%), hypertensive disease (28.7%), ischemic heart
disease (38.7%), and renal disease (41.7%).
In the adjusted logistic regression model—which included age,
sex, race, ethnicity, COPD, hypertensive disease, ischemic heart dis-
ease, renaldisease, andnumberof encounters—all nonwhitegroups
had greater odds than whites of having T2DM; each medical diag-
nosis and number of encounters were associated with increased
odds of having T2DM.
3.3. Prevalence of psychiatric diagnoses by T2DM (Table 2)In the overall sample (n=170,853), all of the psychiatric diag-
nosis categories examinedweremore prevalent among adultswith
T2DM than among those without (Fig. 1). Overall, 37.36% of adults
with T2DM had a psychiatric diagnosis compared with 18.93%
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Aig. 1. Prevalence of psychiatric conditions. This ﬁgure displays the prevalence of
bbreviations: CI, conﬁdence interval; T2DM, type 2 diabetes.
f adults without T2DM. Prevalent diagnoses among adults with
2DM were mood (21.22%), SUD (any SUD 17.02%: tobacco 13.25%,
lcohol 4.00%, illicit drugs 4.22%), and anxiety diagnoses (13.98%),
ollowed by schizophrenia/psychotic (3.38%) and other psychiatric
iagnoses (<1%).
.4. Adjusted OR of psychiatric diagnoses by T2DM (Table 3)We conducted an adjusted logistic regression analysis to
etermine the strength of the association between T2DM and each
sychiatric diagnosis, while controlling for age, sex, race, ethnicity,
nd number of encounters. Except for alcohol use and somatic
able 2
revalence of psychiatric conditions by T2DM (percent and 95% CI).
Psychiatric diagnosis,
prevalence
T2DM % (95% CI)
Overall Aged 18–35
Alcohol Yes 4.00 (3.70–4.31) 3.66 (2.79–4.70)
No 2.27 (2.20–2.35) 1.57 (1.48–1.66)
Tobacco Yes 13.25 (12.74–13.79) 11.35 (9.83–13.01)
No 5.58 (5.47–5.70) 3.21 (3.08–3.34)
Drugs Yes 4.22 (3.91–4.54) 5.93 (4.82–7.20)
No 2.07 (2.00–2.14) 1.80 (1.71–1.90)
Any substance Yes 17.02 (16.44–17.60) 16.14 (14.36–18.05)
No 7.96 (7.83–8.10) 5.41 (5.25–5.58)
Schizophrenia or
psychotic
Yes 3.38 (3.11–3.67) 3.97 (3.07–5.05)
No 0.98 (0.93–1.03) 0.65 (0.59–0.71)
Mood Yes 21.22 (20.59–21.86) 19.67 (17.74–21.72)
No 9.55 (9.40–9.69) 6.41 (6.24–6.59)
Anxiety Yes 13.98 (13.45–14.52) 11.79 (10.24–13.48)
No 7.53 (7.39–7.66) 5.64 (5.47–5.81)
Personality Yes 0.91 (0.77–1.07) 1.70 (1.12–2.47)
No 0.36 (0.33–0.39) 0.34 (0.30–0.38)
Somatic Yes 0.44 (0.34–0.55) 0.76 (0.39–1.32)
No 0.18 (0.16–0.20) 0.11 (0.09–0.14)
Disruptive behavioral Yes 0.16 (0.10–0.23) 0.50 (0.22–0.99)
No 0.06 (0.05–0.07) 0.07 (0.05–0.09)
None of the above Yes 62.64 (61.89–63.38) 66.08 (63.69–68.41)
No 81.07 (80.88–81.27) 86.57 (86.32–86.81)
ote. Due to small patient counts in several cells, all reported conﬁdence intervals are exa
ll abbreviations can be found in Table 1.hiatric conditions among adults aged 18 or older, by T2DM (percent and 95% CI).
diagnoses, T2DM was associated with elevated odds of having
each of the other psychiatric categories in the overall sample
(n=170,853). We also stratiﬁed the analysis by age, and a similar
pattern was observed across age groups. Additionally, T2DM was
associated with elevated odds of having alcohol use disorder in
the 18–35 age group.
3.5. Adjusted OR of comorbid SUD and psychiatric diagnoses
among adults with T2DM (Table 4)
Finally, we conducted adjusted logistic regression analyses
of adults with T2DM (n=16,243) to determine the strength of
Aged 36–50 Aged 51–64 Aged 65 and older
5.85 (5.15–6.62) 4.35 (3.83–4.91) 2.22 (1.83–2.67)
3.18 (3.01–3.36) 3.18 (2.96–3.40) 1.83 (1.62–2.06)
17.43 (16.27–18.64) 15.36 (14.43–16.33) 8.14 (7.39–8.93)
7.67 (7.41–7.93) 8.97 (8.62–9.33) 6.19 (5.81–6.60)
6.60 (5.85–7.41) 3.57 (3.10–4.08) 2.50 (2.08–2.97)
2.98 (2.81–3.15) 1.73 (1.57–1.90) 1.47 (1.28–1.68)
21.74 (20.47–23.05) 18.84 (17.82–19.88) 11.45 (10.58–12.37)
10.53 (10.24–10.84) 11.19 (10.80–11.59) 8.38 (7.93–8.84)
3.49 (2.94–4.10) 2.66 (2.26–3.11) 3.92 (3.40–4.49)
0.97 (0.87–1.07) 1.15 (1.02–1.29) 2.44 (2.19–2.70)
22.61 (21.32–23.94) 22.24 (21.16–23.35) 19.45 (18.36–20.57)
11.29 (10.98–11.60) 12.93 (12.51–13.35) 15.00 (14.43–15.59)
14.64 (13.56–15.77) 14.37 (13.46–15.31) 13.71 (12.77–14.70)
8.44 (8.17–8.71) 9.74 (9.38–10.12) 10.88 (10.38–11.39)
1.54 (1.19–1.97) 0.71 (0.51–0.96) 0.38 (0.23–0.59)
0.47 (0.41–0.55) 0.30 (0.23–0.37) 0.27 (0.19–0.37)
0.72 (0.48–1.04) 0.39 (0.24–0.59) 0.16 (0.07–0.31)
0.23 (0.19–0.29) 0.24 (0.18–0.31) 0.21 (0.14–0.30)
0.27 (0.14–0.49) 0.11 (0.04–0.23) 0.02 (0.00–0.11)
0.07 (0.05–0.11) 0.04 (0.02–0.07) 0
60.13 (58.60–61.65) 60.77 (59.48–62.04) 65.66 (64.33–66.98)
77.80 (77.39–78.20) 74.75 (74.20–75.29) 72.79 (72.06–73.51)
ct.
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Table 3
Adjusted logistic regression analysis of psychiatric diagnosis in relation to T2DM.
Psychiatric diagnosis Adjusted OR (95% CI)
Overall
n=170,853
Aged 18–35
n=76,297
Aged 36–50
n=44,514
Aged 51–64
n=30,441
Aged 65 and older
n=19,601
Alcohol 1.041 (0.950–1.143) 1.488 (1.124–1.970) 1.110 (0.954–1.292) 0.923 (0.791–1.078) 0.906 (0.718–1.143)
Tobacco 1.226 (1.160–1.296) 1.425 (1.199–1.694) 1.413 (1.283–1.555) 1.170 (1.069–1.280) 1.041 (0.916–1.182)
Drugs 1.217 (1.109–1.335) 1.375 (1.095–1.728) 1.156 (0.999–1.338) 1.272 (1.062–1.523) 1.445 (1.147–1.820)
Any substance (alcohol, tobacco, or drugs) 1.236 (1.176–1.299) 1.488 (1.284–1.724) 1.349 (1.236–1.472) 1.195 (1.099–1.298) 1.124 (1.007–1.254)
Schizophrenia or psychotic 1.673 (1.500–1.866) 2.731 (2.051–3.638) 1.993 (1.619–2.454) 1.603 (1.297–1.980) 1.498 (1.246–1.802)
Mood 1.364 (1.301–1.429) 1.607 (1.397–1.848) 1.465 (1.339–1.603) 1.429 (1.317–1.549) 1.238 (1.133–1.354)
Anxiety 1.127 (1.068–1.190) 1.094 (0.925–1.293) 1.186 (1.069–1.316) 1.087 (0.990–1.194) 1.126 (1.016–1.248)
Personality 1.780 (1.455–2.176) 2.057 (1.345–3.145) 1.838 (1.353–2.496) 1.959 (1.303–2.943) 1.439 (0.815–2.540)
Somatic 1.070 (0.807–1.417) 1.827 (0.961–3.476) 1.280 (0.827–1.983) 0.885 (0.529–1.478) 0.607 (0.273–1.350)
Disruptive behavioral 1.771 (1.094–2.869) 2.615 (1.170–5.845) 1.465 (0.713–3.010) 1.449 (0.500–4.199) –
Note. For all age category columns, the following model was used to calculate ORs and CIs: psychiatric condition as predicted by T2DM, continuous age, sex, race, ethnicity,
and log base 10 of the number of patient encounters. The race variable in the model consists of these collapsed values: black, white, and other. For the overall column, the
same model as above was used to calculate ORs and CIs, with the addition of stratiﬁcation by age category. Bold face: P<0.05
All abbreviations can be found in Table 1.
Table 4
Adjusted logistic regression model of psychiatric disorder in relation to substance use disorder diagnosis among adults with a T2DMa diagnosis.
Psychiatric diagnosis Adjusted OR (95% CI)
Overall
n=16,243
Aged 18–35
n=1586
Aged 36–50
n=4016
Aged 51–64
n=5638
Aged 65 and older
n=5003
Schizophrenia or psychotic 2.975 (2.454–3.607) 3.774 (2.160–6.597) 2.735 (1.904–3.928) 4.496 (3.141–6.437) 1.993 (1.345–2.953)
Mood 2.229 (2.016–2.465) 2.546 (1.814–3.573) 3.052 (2.522–3.694) 2.084 (1.767–2.458) 1.638 (1.324–2.026)
Anxiety 1.857 (1.656–2.081) 1.977 (1.324–2.952) 1.960 (1.583–2.428) 1.638 (1.357–1.978) 1.974 (1.565–2.490)
Personality 3.649 (2.559–5.203) 7.836 (3.046–20.158) 3.726 (2.144–6.475) 2.571 (1.291–5.118) 2.031 (0.707–5.835)
Somatic 2.831 (1.707–4.694) 6.675 (1.666–26.750) 2.474 (1.134–5.400) 2.141 (0.864–5.306) 2.542 (0.529–12.212)
Disruptive behavioral 4.682 (2.033–10.782) 3.915 (0.803–19.075) 8.286 (2.097–32.739) 2.888 (0.505–16.512) –
Note. For all age category columns, the following model was used to calculate ORs and CIs: psychiatric condition as predicted by any substance use diagnosis, continuous
age, sex, race, ethnicity, COPD, hypertensive disease, ischemic heart disease, renal disease, and log base 10 of the number of patient encounters. The race variable in the
model consists of these collapsed values: black, white, and other. For the overall column, the same model as above was used to calculate ORs and CIs, with the addition of
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a Analysis sample: patients had a T2DM diagnosis.
he association between SUD and each of the mental diagnoses,
espectively, while controlling for age, sex, race, ethnicity, COPD,
ypertensive disease, ischemic heart disease, renal disease, and
umber of encounters. An SUD diagnosis was positively associated
ith having schizophrenia/psychotic, mood, anxiety, personality,
omatic, and disruptive behavioral diagnoses, respectively. A simi-
ar patternwas foundwhen the analysiswas stratiﬁedbyagegroup.
. Discussion
This analysis of EHR data from 170,853 adult patients provides
mportant clinical evidence of the high prevalence of SUDand other
sychiatric comorbidities in adults with T2DM. First, all non-white
roups had higher odds of T2DM than whites. Second, all psychi-
tric diagnosis categories that we examinedwere found to bemore
revalent among adults with T2DM than among those without
2DM; a similar pattern (except for somatic diagnosis) was iden-
iﬁed by adjusted logistic regression analyses. Third, among adults
ith T2DM, SUD was positively associated with schizophrenia,
ood, anxiety, personality, somatic, and disruptive behavioral dis-
rders, respectively, indicating multi-comorbidity. These ﬁndings
ncrease our understanding of the prevalence of SUD and related
sychiatric comorbidities by T2DM status, and have implications
or SUD, psychiatric screening, and the development of collabo-
ative care models to improve health outcomes..1. What this study adds to our knowledge
Prior research on mental health conditions in patients with
iabetes has mainly focused on depression or anxiety, and usedgnosis” (alcohol, tobacco, or drug use). Bold face: P<0.05
self-reported psychiatric and medical status derived from survey
questions answered by the sampled participants (Roy and Lloyd,
2012; Smith et al., 2013). SUDs are among the leading conditions
contributing to high rates of hospital readmissions (Jiang and Wier,
2010), but little is known about SUD prevalence and SUD-related
comorbidity in adults with T2DM. Due to health care reform (e.g.,
the 2010 Affordable Care Act and the Mental Health Parity and
Addiction Equity Act of 2008), SUD treatment services are consid-
ered an essential health beneﬁt, and the development of integrated
behavioral (especially SUDs) and physical care models to improve
behavioral health care in primary care has become a priority (Tai
and Volkow, 2013). The use of patients’ medical records data from
EHRs to aide data collection and monitor clinical outcomes is rec-
ognized as a fundamental element in practical clinical research for
developing learning healthcare systems (IOM, 2010). The Health
Information Technology for Economic and Clinical Health (HITECH)
Act also promotes national adoption of the EHR in clinical care.
Consequently, the EHR is a pivotal tool for facilitating the imple-
mentation of integrated SUD care and tracking clinical outcomes
for both clinical and research purposes (Tai et al., 2012). The EHR
captures a wide range of psychiatric diagnoses from a large and
broad patient population. Our study analyzed EHR data from a
large sample, in hopes of providing much-needed SUD and related
psychiatric comorbidity data on patients in real-life medical sett-
ings to inform EHR-enabled research and clinical efforts related to
screening and integrated care. The results of our study add new
and comprehensive psychiatric proﬁles (e.g., SUDs, schizophrenia,
personality, somatic diagnoses) for adults with and without T2DM
in medical settings, which may not be captured by community
surveys.
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One critical ﬁnding concerns the high prevalence of any SUD
17.02%) among adults with T2DM compared with adults without
2DM (7.96%); there is a pervasive pattern in comorbid SUD with
ental diagnoses. National survey data estimate that 12.9–13.6%
f adults aged ≥18 had current nicotine dependence, and that 7.0%
nd 2.5% of adults had an alcohol and drug use disorder in the past
ear, respectively (SAMHSA, 2014). We found that 13.25%, 4.00%,
nd 4.22%, had a documented tobacco, alcohol, and drug use dis-
rder diagnosis, respectively. Moreover, among adults with T2DM,
ore than 1 in 3 (37.36%) had a documented psychiatric diagno-
is in their EHRs, and SUD was positively associated with each of
he 6 mental diagnosis categories examined, highlighting a need
o increase SUD research in individuals with T2DM and to improve
heir SUD care. The co-occurrences of SUD with mental disorders
ay be inﬂuenced by multiple pathways (e.g., self-medication,
ommon risk factors, diathesis-stress) (Conway et al., 2006; Green,
005; Ingram and Luxton, 2005). Importantly, our study adds new
stimates by revealing a particularly burdensome SUD and psy-
hiatric multi-comorbidity among adults with T2DM in medical
ettings, which may also be related to treatment factors, including
election bias (severity increasing treatment use and diagnoses; De
ert et al., 2009; Vinogradova et al., 2010).
Integrated healthcare models aimed at improving SUD care
mong adults with T2DM should also consider other psychiatric
onditions, especiallymoodand anxiety diagnoses. Consistentwith
HR data from individuals seeking care in behavioral healthcare
linics (Wu et al., 2013a,b), we found that mood (21.22%), SUD
17.02%), and anxiety (13.98%) diagnoses are themost commondis-
rders in the sample. National survey data estimate that 19.54% of
dults aged ≥18 have a mood disorder and 16.16% have an anx-
ety disorder in their lifetime (Kessler et al., 2005). Additionally,
epression was nearly twice as common among adults with T2DM
19.1%, range 6.5–33%) comparedwith thosewithout T2DM (10.7%,
ange 3.8–19.4%) (Roy and Lloyd, 2012). Another review found that
4% of adults with diabetes had a current anxiety disorder (Grigsby
tal., 2002). TheassociationbetweenT2DMandmood/anxietyhave
eensuggested tobemultifactorial innature, including lifestyleand
reatment factors that are associated with depression or obesity
e.g., physical inactivity, use of some antidepressants or antipsy-
hotics; Faith et al., 2011; Grundy et al., 2014; Patten et al., 2011;
amaswamy et al., 2006) as well as diabetes-related stress (De
ert et al., 2009; Ducat et al., 2014). This study adds newer clinical
vidence that reveals a high prevalence of SUDs and a pervasive
attern of SUD-psychiatric comorbidity among adults with T2DM.
hese results demonstrate a critical need to address the potential
mpact of mood/anxiety diagnosis on severity and treatment com-
liance for adults living with both T2DM and SUD (Ducat et al.,
014; Najt et al., 2011).
.2. Limitations and strengths
Our study results should be interpreted within the following
imitations. This analysis focuses on understanding the prevalence
f SUDandmental diagnoses amongpatientwithT2DM,and results
eﬂect associations, not causality. Results arebasedonpatientswho
ccessed healthcare at one of the clinics/practices of a large aca-
emic healthcare system. Although the EHR data that we studied
ncluded diverse racial/ethnic groups in the communities, results
re not completely generalizable to patients in different regions.
heEHRsmay tend to include severeor frequent treatment-seeking
eople, so those with T2DM, but without manifested medical
onditions, might not be diagnosed. Nonetheless, disorders with
bjective diagnostic features like diabetes have a high level of EHR
oding accuracy (Jordan et al., 2004; Pringle et al., 1995).
Similar to other medical conditions, underdiagnoses or misclas-
iﬁcation of SUD and psychiatric diagnoses are possible (Banta andendence 156 (2015) 162–169 167
Montgomery, 2007; Menchetti et al., 2009; Rockett et al., 2003).
Diagnoses in EHRs are based on actual treatment as part of usual
care settings, which are determined by using the available infor-
mation from medical histories and evaluations, patient reports,
and interactions among providers, patients, and family members.
Since it is not feasible to assess all diagnoses systematically, people
with mild forms of a disorder or those who did not disclose symp-
toms might not be recognized. Detection of SUD and psychiatric
disorders may be inﬂuenced by patient demographics, presenta-
tion of symptoms, treatment-seeking frequency, and clinicians’
specialties (Docherty, 1997; Garland et al., 2005; Herran et al.,
1999; Menchetti et al., 2009). Nevertheless, having a longstand-
ing provider-patient relationship, using criteria for diagnoses, and
using EHRs systematically (allowing reevaluation and monitoring
of the problems) are important factors for improving diagnostic
accuracy (Pringle et al., 1995; van Weel-Baumgarten et al., 2000;
van Weel-Baumgarten and Lucassen, 2009). Overall, our results
should be considered conservative estimates, particularly for SUDs,
which may be underestimated due to perceived stigma and a lack
of systematic screening in general medical settings (Tai et al.,
2012).
Our examination of EHR data also has important strengths.
Results reﬂect clinical patterns among patients in real-world gen-
eral medical settings in the Southeastern United States. To our
knowledge, our study includes the largest sample of patients ever
examined for SUD and related psychiatric comorbidity by T2DM
status in the United States. This large sample size allowed stratiﬁed
analyses by age group to inform reliability of estimates. The Duke
University Health System is among the pioneers developing EHRs
for its clinics/practices. In 1968, Duke investigators began devel-
oping a working prototype of a general purpose electronic medical
record (EMR) that eventually evolved into one of the ﬁrst EMRs
in the United States (Duke University, 2010). The long-term use
of an EMR to enhance healthcare and the longitudinally captured
EHRs may improve completeness of diagnostic and treatment data
(Horvath et al., 2014; Pringle et al., 1995; Silfen, 2006; Silow-Carroll
et al., 2012; Weiner et al., 2007).
4.3. Conclusion and clinical implications
The prevalence of T2DM in this study is consistent with the
national estimate (ADA, 2015). We found that more than 1 in 3
adults with T2DM had a documented psychiatric diagnosis. Indi-
viduals that have diabetes with complications, SUD, or chronic
mental diagnoses use more costly inpatient care than those with-
out such diagnoses (Jiang and Wier, 2010; Jiang et al., 2014); these
co-existences further aggravate morbidity and increase healthcare
expenditures (Ducatet al., 2014;Vinogradovaetal., 2010). Themost
costly 10% of the patient population in the United States accounted
for 66% of total healthcare expenditures (Cohen, 2014). Therefore,
the identiﬁed SUD-psychiatric comorbidities among adults with
T2DM highlight a critical need to apply preventive services (e.g.,
screening, intervention) in primary care in order to enhance early
detectionand intervention forSUDandassociatedpsychiatricprob-
lems. There is a tremendous demand for coordinated care models
aimed at improving behavioral health and reducing avoidable hos-
pitalizations for patients with multi-comorbidities (Katon et al.,
2012). Research efforts are needed to identify effective approaches
for screening substance misuse/SUD, implementing interventions,
and coordinating referrals to SUD treatment and follow-ups for
individuals with diabetes (Ghitza et al., 2013). There are limited
data available to inform smoking cessation in peoplewith diabetes.
Given that tobacco use disorder was the most prevalent SUD in our
sample, this ﬁnding reafﬁrms the need for clinical research to test
tailored smoking cessation interventions for people with diabetes
(Nagrebetsky et al., 2014). Collaborative care models have been
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ound to improve health outcomes for individuals with depression
nd diabetes, and this line of efforts should be expanded to also
ddress SUD and related psychiatric comorbidity for people with
iabetes (Huang et al., 2013).
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